Koers Point Capital Inc Other OTC
Aandelen
US73052R1041
Farmaceutische producten
Omzet 2024 * | 72K 67,34K | Omzet 2025 * | 72K 67,34K | Marktkapitalisatie | 5,26 mln. 4,92 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -4 mln. -3,74 mln. | Nettowinst (verlies) 2025 * | -8 mln. -7,48 mln. | EV/omzet 2024 * | 73,1 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 73,1 x |
K/w-verhouding 2024 * |
-3,3
x | K/w-verhouding 2025 * |
-2,64
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 86,01% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Eric Weisblum
CEO | Chief Executive Officer | 54 | 13-07-10 |
Daniel Ryweck
DFI | Director of Finance/CFO | 59 | 27-09-22 |
James Kuo
CTO | Chief Tech/Sci/R&D Officer | 58 | 01-09-22 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Eric Weisblum
CEO | Chief Executive Officer | 54 | 13-07-10 |
Wayne Linsley
BRD | Director/Board Member | 67 | 16-01-20 |
Kevin Muñoz
BRD | Director/Board Member | 46 | 01-10-20 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-4,66% | 86,13 mld. | |
+1,32% | 39,82 mld. | |
-19,27% | 30,42 mld. | |
+57,86% | 25,23 mld. | |
-16,09% | 15,36 mld. | |
-9,14% | 11,95 mld. | |
-17,69% | 11,6 mld. | |
-43,00% | 11,51 mld. | |
+5,24% | 8,71 mld. |